The effect of statin use on lens density as assessed by pentacam hr® lens densitometry in adults

Main Article Content

Akin Cakir
Alptug Tokatli
Taner Kar
Yildiray Yildirim
Eyup Duzgun
Emrah Erdal


Objective: To investigate the association between statin use and cataract development by using Pentacam HR Scheimpflug camera system.

Material and Methods: Total 208 age and sex matched participants were included in this prospective, case-control study. 104 long-term statin users as study group and 104 non-statin users as control group constituted to the study. Lens densitometry measurements were performed with the Pentacam HR® (Oculus, Wetzlar, Germany) from three areas (anterior, nuclear, and posterior). These measurements were compared between the groups.

 Results: There were no significant difference at the basic clinical variables (p=0.121, p=0.778). The mean duration of statin use of the study group was 5,4±4,3 years. The mean value of lens densitometry measurement at nuclear area tended to be lower in statin users than controls, but difference was not statistically significant (9.20±1.00 vs 9.35±1.20; p:0.346). However, the mean lens densitometry values at the anterior and posterior areas of statin users were found to be significantly higher than controls (10.44±1.32 vs 9.16±1.09;p<0.001; 7.86±0.49 vs 7.63±0.38; p<0.001,respectively).

Conclusion: The current study finds that long-term statin use seems to be associated with an increased risk of cortical cataracts (anterior-posterior) but not incidence of nuclear cataracts.


Download data is not yet available.

Article Details

How to Cite
Cakir, A. ., Tokatli, A. ., Kar, T. ., Yildirim, Y. ., Duzgun, E. ., & Erdal, E. . (2016). The effect of statin use on lens density as assessed by pentacam hr® lens densitometry in adults. Medical Science and Discovery, 3(6), 245–249. Retrieved from
Research Article


World Health Organization Office of Information. Blindness and Visual Disability: Part II: Major Causes Worldwide. WHO fact sheet no 143. Geneva: WHO; 1997.

Leuschen J, Mortensen EM, Frei CR, et al. Association of statin use with cataracts: a propensity score-matched analysis. JAMA Ophthalmol. 2013;131(11):1427-34.

Davignon J, Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 1999;10(6):543–559.

Lai CL, Shau WY, Chang CH, et al. Statin use and cataract surgery: a nationwide retrospective cohort study in elderly ethnic Chinese patients. Drug Saf. 2013;36(10):1017-24.

Klein BEK, Klein R, Lee KE, et al. Statin use and incident nuclear cataract. JAMA 2006;295(23):2752–2758.

Tan JSL, Mitchell P, Rochtchina E, et al. Statin use and the long term risk of incident cataract: The Blue Mountains Eye Study. Am J Ophthalmol 2007;143(4):687–689.

Chodick G, Heymann AD, Flash S, et al. Persistence with statins and incident cataract: A population-based historical cohort study. Ann Epidemiol 2010;20(2):136–142.

Fong DS, Poon KYT. Recent Statin Use and Cataract Surgery. Am J Ophthalmol 2012;153:222–228.

Schmidt J, Schmitt C, Hockwin O. No lens changes caused by simvastatin results from a prospective drug safety study. Lens Eye Toxic Res 1990;7:643–50.

Harris ML, Bron AJ, Brown NA, et al. Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group. Br J Ophthalmol 1995;79:996–1002.

Qian W, Soderberg PG, Chen E, et al. 3 year simvastatin treatment and lens nuclear back scattering. Br J Ophthalmol 2000;84:512–16.

Smeeth L, Hubbard R, Fletcher A.E. Cataract and the use of statins: a case-control study. Q J Med 2003;96:337–343.

Manchan CM, Hrynchak PK, Irvin EL. Age-related cataract is associated with type 2 diabetes and statin use. Optom Vis Sci. 2012;89:1165-1171.

Wise SJ, Nathoo NA, Etminan M, et al. Statin use and risk for cataract: a nested case-control study of 2 populations in Canada and United States. Can J Cardiol. 2014;30:1613-1619.

Klein BE, Cruickshanks KJ, Klein R. Leisure time,sunlight exposure and cataracts. Doc Ophthalmol.1995;88:295-305.

Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337:8-14.

Grosser N, Hemmerle A, Berndt G, et al. The antioxidant defense protein heme oxygenase 1 is a novel target for statins in endothelial cells. Free Radic Biol Med. 2004;37:2064-2071.

Stoll LL, McCormick ML, Denning GM, et al. Antioxidant effects of statins. Drugs Today. 2004;40:975-990.

Klein BE, Klein R, Lee KE, et al. Markers of inflammation, vascular endothelial dysfunction, and age-related cataract. Am J Ophthalmol. 2006;141:116-122.

Leung BP, Sattar N, Crilly A, et al. A novel antiinflammatory role for simvastatin in inflammatory arthritis. J Immunol. 2003;170:1524-1530.

Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286:64-70.

Gerson RJ, MacDonald JS, Alberts AW, et al. On the etiology of subcapsular lenticular opacities produced in dogs receiving HMG-CoA reductase inhibitors. Exp Eye Res. 1990;50:65-78.

Cenedella RJ. Cholesterol and cataracts. Surv Ophthalmol. 1996;40(4):320-337.

Mori M, Li G, Abe I, et al. Lanosterol synthase mutations cause cholesterol deficiency-associated cataracts in the Shumiya cataract rat. J Clin Invest. 2006;116(2):395-404.

Zhao L, Chen XJ, Zhu J, et al. Lanosterol reverses protein aggregation in cataracts. Published online 22 July 2015. doi:10.1038/nature14650.

Xu K, Hao Y. Mol Med Rep. Determination of the density of human nuclear cataract lenses. Mol Med Rep. 2013 Nov;8(5):1300-1304